Evidence map›Paper›PMID 21207011›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2011

Vitamin D in organ transplantation.

E M Stein, E Shane

Abstract readReview
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 87 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Post-Transplant Vitamin D Deficiency in Lung Transplant Recipients: Impact on Outcomes and Prognosis.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Observational
  9. Article
  10. Review
  11. Bone and Mineral Disease in Kidney Transplant Recipients.Clinical journal of the American Society of Nephrology : CJASN · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

E M SteinDepartment of Medicine, Columbia University Medical Center, 630 West 168th Street, PH8-864, New York, NY 10032, USA. es2029@columbia.edu
E Shane
Columbia University · USColumbia University Irving Medical Center · US

Funding

Idiopathic Osteoporosis in Premenopausal WomenK24AR052665 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHANE, ELIZABETH J · 2005 to 2014
$1.8M
Chronic Kidney Disease and PTH: Effects on the Postmenopausal SkeletonK23DK084337 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STEIN, EMILY MARGARET · 2009 to 2013
$749k
NIAMS NIH HHS K24 AR052665NIDDK NIH HHS K23 DK084337
6 · The paper itself

Abstract

Vitamin D deficiency is prevalent among patients with end-stage organ failure awaiting transplant. Low serum 25-hydroxyvitamin D (25-OHD) levels in these patients may be related to many disease-specific factors, as well as decreased sunlight exposure and limited intake of foods containing vitamin D. Low serum 25-OHD levels are also extremely common following solid organ transplantation, both during the immediate postoperative period and in long-term graft recipients. Demographic and lifestyle factors are important in determining D status in transplant recipients. Worse vitamin D status is associated with poorer general health, lower albumin, and even decreased survival among these patients. Although several studies have demonstrated that active forms of vitamin D and its analogues prevent bone loss following transplantation, the data do not show consistent benefit. These therapies may have particular utility after renal transplantation. However, given the narrow therapeutic window with respect to hypercalcemia and hypercalciuria, and the demonstrated efficacy of bisphosphonates to prevent post-transplantation bone loss, we regard these agents as adjunctive rather than primary therapy for transplantation osteoporosis. The effects of 1,25(OH)(2)D on the immune system, which are still being elucidated, may have potential for reducing infections and preventing allograft rejection after transplantation.

Indexed as

Bone Density Conservation AgentsBone ResorptionCholecalciferolClinical Trials as TopicErgocalciferolsHeart TransplantationHumansKidney TransplantationLiver TransplantationLung TransplantationOrgan TransplantationVitamin DVitamin D Deficiency25-hydroxyvitamin DBone Density Conservation AgentsCholecalciferolErgocalciferolsVitamin D

Identifiers

PMID21207011
PMCPMC4139072
OpenAlexW2001344436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.